View Post

Immunomedics Announces Publication of Triple-Negative Breast Cancer Data With Sacituzumab Govitecan in the New England Journal of Medicine

In Clinical Trials by Barbara Jacoby

Source: Immunomedics From: globenewswire.com Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that updated data from the Phase 2 study of sacituzumab govitecan in patients with metastatic triple-negative breast cancer (mTNBC) were published on NEJM.org as part of the February 21 print issue of the New England …

View Post

Should Patients Have to Pay for the Drugs They Helped Test?

In Clinical Trials by Barbara Jacoby

By: Len Lichtenfeld, M.D. From: curetoday.com Here is an interesting situation that I learned about recently, and it has me asking a question I hadn’t thought of before: What is our obligation to those who participated in and benefited from clinical trials but then are charged huge copays to continue taking the drugs they helped develop when the medi­cines get …

View Post

AIVITA Completes Treatment of First Patient in Phase 2 Ovarian Cancer Trial

In Clinical Trials by Barbara Jacoby

Source: AIVITA Biomedical, Inc. From: prnewswire.com AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today that its first patient has completed treatment in its multi-center Phase 2 ROOT OF CANCER ovarian cancer trial. The patient has received the eighth and final dose of the study therapy under the guidance of Principal Investigator Dr. Lisa Abaid …

View Post

Torque Announces Clinical Trial Collaboration with Merck

In Clinical Trials by Barbara Jacoby

Source: Torque From: prnewswire.com Phase 1/2 combination clinical trial evaluating Torque’s Deep IL-15 Primed T Cells (TRQ-1501) and KEYTRUDA® (pembrolizumab) for the treatment of multiple cancer indications Torque, a clinical-stage immuno-oncology company developing first-in-class Deep Primed™ T Cell Therapeutics to direct immune power deep within the tumor microenvironment, announced today that it has entered into a clinical trial collaboration agreement …

View Post

Structural and clinical barriers keep 3 of 4 cancer patients from participating in trials

In Clinical Trials by Barbara Jacoby

By: Diane Mapes From: fredhutch.org A new meta-analysis led by Dr. Joseph Unger of Fred Hutchinson Cancer Research Center has revealed that structural and clinical barriers prevent more than 3 out of 4 cancer patients from participating in clinical trials. The study is part of an ongoing effort to understand why patient participation is so low in cancer clinical trials. …

View Post

Enrollment Complete in Phase 2 Trial of NeuVax-Herceptin for HER2-Positive, High-Risk Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Alice Melão From: breastcancer-news.com The investigator-sponsored trial studying a combination of NeuVax (nelipepimut-S, NPS) and Herceptin (trastuzumab) as a maintenance treatment for HER2-positive breast cancer at high risk of recurrence has completed patient enrollment, Sellas Life Sciences, NeuVax’s developer, has announced. Top-line data from the trial is expected by the end of 2019. “The completion of enrollment of this Phase 2 clinical …

View Post

FDA Approves First Immunotherapy for Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Nick Mulcahy From: medscape.com The US Food and Drug Administration today granted accelerated approval to atezolizumab (Tecentriq, Genentech/Roche) plus the chemotherapy nab-paclitaxel (Abraxane, Celgene) for the first-line treatment of unresectable locally advanced or metastatic, PD-L1-positive triple-negative breast cancer (TNBC). Atezolizumab is the first immunotherapy to be approved for breast cancer. The approval is based on progression-free survival results and continued …

View Post

Tomorrow’s breast cancer therapy – today

In Clinical Trials by Barbara Jacoby

By: KATE ANDREWS From: chesterfieldobserver.com From ‘doing less’ to immunotherapy, clinical trials offer patients new options Women in the United States have a 1-in-8 chance of being diagnosed with breast cancer, and the disease has garnered significant attention in recent years, with football players donning pink socks and women running 5K races to raise money for research. And yet, despite …

View Post

U of S ‘assassin antibody’ shows promise in killing cancer

In Clinical Trials by Barbara Jacoby

By: Chris Vandenbreekel From: .cjme.com A promising research breakthrough at the University of Saskatchewan could end up being a cure for colorectal cancer. A research team has developed an “assassin antibody” that attaches itself to colorectal cancer cells and destroys them with an astonishing success rate. “We’ve had up to 80 per cent of animals completely disease free,” research lead …

View Post

Margetuximab Improves Survival as HER+ Breast Cancer Treatment in Phase 3 Trial

In Clinical Trials by Barbara Jacoby

By: Jennifer Barrett From: specialtypharmacytimes.com Margetuximab, an investigational monoclonal antibody, improved progression-free survival (PFS) when used in combination with chemotherapy in patients with human epidermal growth factor receptor 2- (HER2) positive metastatic breast cancer, according to new data from a pivotal phase 3 trial. The SOPHIA study, which enrolled 536 patients, evaluated margetuximab in combination with chemotherapy compared with trastuzumab …